Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that James Latham will join as Development and Leasing Director in January 2021.
Having previously worked for SBC in a consulting role with Carter Jonas, James will be joining the team full-time to take on an asset and development management position, responsible for leasing, planning and property development activities, working both with the in-house team at SBC and external experts as required.
James has a first-class degree from the University of Reading in Land Management and has been a Member of the Royal Institution of Chartered Surveyors since 2013. With eleven years’ experience working in the South East property market, James joins SBC from Carter Jonas, a UK based real estate agency and property consultancy. Prior to this experience in 2016, James worked for a developer, Guildhouse UK Ltd in London as an Asset and Development Manager.
Dr Sally Ann Forsyth, CEO at SBC, said, “We are delighted to welcome James to SBC and look forward to him joining the team full-time. With his substantial experience in the Life Sciences sector and in-depth knowledge of the region, James will be a fantastic asset to the team as our new Development and Leasing Director.”
James Latham commented, “I am delighted to join the SBC team in a new full-time role. It’s an exciting place to work; it has a vibrant ecosystem that prioritises innovation and collaboration and I look forward to working with the team to support SBC’s growing occupier base, bring forward new projects and promote the growth of the cluster.”
About Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst is a world-leading science park of global significance and located at the centre of the largest cluster of cell and gene therapy companies in Europe. Since its opening in 2012, occupier companies have secured £1.6bn in funding and it has attracted over 40 high-profile occupier businesses and world-class research organisations to Stevenage. This includes the Cell and Gene Therapy Catapult Manufacturing Centre which is currently undergoing expansion to help support up to 12 cell and gene therapy companies.